Aulitzky W E, Schuler M, Peschel C, Huber C
IIIrd Department of Internal Medicine, Medical School, Johannes Gutenberg University, Mainz, Germany.
Drugs. 1994 Nov;48(5):667-77. doi: 10.2165/00003495-199448050-00002.
With interleukins (IL), a new class of potential drugs has been introduced into clinical research. These signal peptides are involved in the regulation of many physiological and pathophysiological processes. IL-1, -2, -3, -4, -6 and -11 have been tested in clinical trials. The growth promoting, growth inhibiting or immunomodulatory activities of interleukins represent the theoretical basis for large scale clinical testing, predominantly in malignant disease. Dose-dependent effects on numbers of peripheral blood cells and recovery from bone marrow failure have been demonstrated for IL-1, -3, -6 and -11. Phase III trials are in progress to determine their value for clinical practice. However, investigations on the immunomodulatory activities proved to be more difficult. This is because key mechanisms for successful treatment of malignant disease by immunomodulation are not clearly defined and the methodology for assessment of immunostimulatory effects is not well established. Besides treatment of renal cell carcinoma and malignant melanoma with IL-2, no successful trials have been reported. However, phase I clinical trials with IL-1, IL-4 and IL-6 have just been completed. Thus, it seems too early to conclude on their therapeutic potential.
随着白细胞介素（IL）的出现，一类新型潜在药物已被引入临床研究。这些信号肽参与许多生理和病理生理过程的调节。白细胞介素-1、-2、-3、-4、-6和-11已在临床试验中进行了测试。白细胞介素的促生长、生长抑制或免疫调节活性是大规模临床试验的理论基础，主要用于恶性疾病。白细胞介素-1、-3、-6和-11对外周血细胞数量和骨髓衰竭恢复的剂量依赖性作用已得到证实。目前正在进行III期试验以确定它们在临床实践中的价值。然而，事实证明对免疫调节活性的研究更加困难。这是因为通过免疫调节成功治疗恶性疾病的关键机制尚未明确界定，评估免疫刺激作用的方法也尚未完善。除了用白细胞介素-2治疗肾细胞癌和恶性黑色素瘤外，尚未报道成功的试验。然而，白细胞介素-1、白细胞介素-4和白细胞介素-6的I期临床试验刚刚完成。因此，现在就对它们的治疗潜力下结论似乎还为时过早。
